Study of regulatory communication and risk awareness following the Article 31 referral of Combined Hormonal Contraceptives in relation to thromboembolism

First published: 22/10/2017 Last updated: 02/07/2024





Administrative details

EU PAS number	
EUPAS21356	
Study ID	
26587	
DARWIN EU® study	
No	
Study countries	
Denmark	
Slovakia	
Spain Spain	

United Kingdom
Study description
This study uses surveys and questionnaires to study whether women and prescribers consider the risks of venous thromboembolism when making decisions about the use of combined hormonal contraceptives and what sources of information inform their assessments
Study status Finalised Research institutions and networks
Institutions
Aarhus University & Aarhus University Hospital DEPARTMENT OF CLINICAL EPIDEMIOLOGY Denmark
First published: 20/07/2021
Last updated: 02/04/2024 Institution

Aarhus University & Aarhus University Hospital DEPARTMENT OF CLINICAL EPIDEMIOLOGY

Denmark

First published: 20/07/2021

Last updated: 02/04/2024

Institution

Educational Institution

ENCePP partner

University College London United Kingdom

Networks

Aarhus University Consotrium (ad hoc)

Contact details

Study institution contact

Vera Ehrenstein ve@clin.au.dk

Study contact

ve@clin.au.dk

Primary lead investigator

Henrik Toft Sørensen

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 21/06/2016 Actual: 21/06/2016

Study start date

Planned: 30/01/2017 Actual: 30/01/2017

Date of final study report

Planned: 23/01/2018 Actual: 07/02/2018

Sources of funding

EMA

Study protocol

Study of regulatory communication and risk awareness.pdf (323.88 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition
Human medicinal product

Study type:

Not applicable

If 'other', further details on the scope of the study

Qualitative assessment

Main study objective:

1. To consider the extent to which women and health professionals are aware of the risks of venous thromboembolism (VTE) in users of combined hormonal contraceptives (CHC)2. To document awareness, knowledge, attitudes and practices related to recommendations from regulatory authorities3. To understand how advice from regulators concerning CHC, and specifically how the risks of VTE are perceived

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(G03F) PROGESTOGENS AND ESTROGENS IN COMBINATION PROGESTOGENS AND ESTROGENS IN COMBINATION

Population studied

Short description of the study population

Prescribers and women of childbearing age (between 16 and 49 years of age)

Age groups

- Adolescents (12 to < 18 years)
- Adults (18 to < 46 years)
- Adults (46 to < 65 years)

Special population of interest

Women of childbearing potential not using contraception

Women of childbearing potential using contraception

Estimated number of subjects

1200

Study design details

Data analysis plan

Qualitative assessment of interviews and web survey results

Documents

Study results

qualitative CHC - deliverable 3-final report - revised may18.pdf (1.49 MB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

Interviews, Web surveys

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Data characterisation

Data characterisation conducted

Unknown